Clinical Trials in Alzheimer’s Disease: A Hurdle in the Path of Remedy

Figure 1

The challenges of treating CNS disorders. Both subjective and objective hurdles must be surpassed when developing pharmaceuticals for the treatment of CNS disorders and diseases. Overcoming these hurdles has proven difficult leading to a minimum an increase in time and cost for drug development and at a worse to many drug failures that would otherwise be realized for a systemic-related disorder.